Fluorescent Peptide Conjugates for Intraoperative Imaging

<u>Ali Azhdarinia</u>, Servando Hernandez Vargas, Solmaz AghaAmiri, Sukhen C. Ghosh, Michael P. Luciano, Jennifer M. Bailey-Lundberg, Gregory D. Simonek⁵, Daniel M. Halperin, Hop S. Tran Cao, Naruhiko Ikoma, Martin J. Schnermann

McGovern Medical School, The University of Texas Health Science Center at Houston 1881 East Road, Houston, TX, USA <u>ali.azhdarinia@uth.tmc.edu</u>

Surgical resection is the main treatment for pancreatic neuroendocrine tumors (pNETs) and can be curative if tumors are completely removed ⁽¹⁾. However, the small size of these tumors, presence of multifocal lesions, and frequent lymph node metastases complicate intraoperative localization and margin detection. Positive margins range from 10-30% in pNETs and are strongly associated with increased risk of death. Alternatively, extended pancreatectomy may have unnecessarily wide surgical margins that can cause pancreatic insufficiency in up to 40% of patients and impair quality of life ⁽²⁻⁴⁾. Organ-sparing RO resections could reduce incidences of tumor recurrence and postoperative pancreatic insufficiency but require clear tumor visualization, particularly during minimally invasive surgery where tactile feedback is absent. Since current imaging modalities cannot provide tumor-specific localization in the operating room, more effective imaging approaches are critically needed.

Fluorescence-guided surgery (FGS) is an intraoperative imaging modality that is typically performed in the near-infrared fluorescence (NIRF) spectral range, where the combination of low tissue autofluorescence and high depth penetration can increase detection sensitivity ⁽⁵⁾. Given the near-universal expression of somatostatin receptor subtype 2 (SSTR2) in well-differentiated NETs, we converted the clinically approved SSTR2-targeted radiotracer ⁶⁸Ga-DOTA-TOC into a fluorescent analog, referred to as MMC(IR800)-TOC ⁽⁶⁾. MMC (multimodality chelator) is a cyclen analog that permits bioorthogonal dye conjugation and allowed



Fig. 1. Chemical structure of ⁶⁸Ga-MMC(IR800)-TOC showing a similar footprint to ⁶⁸Ga-DOTA-TOC. MMC

us to utilize quantitative radioactive techniques to demonstrate selective binding in SSTR2 expressing cells and *in vitro* and in animal models. Tumor targeting was further demonstrated by *ex vivo* staining of human pNET biospecimens, suggesting high potential for clinical translation **(2)**.

References:

- [1] Ramage JK, Ahmed A, Ardill J, Bax N, Breen DJ, Caplin ME, et al. Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours (NETs). Gut 2012;61(1):6-32 doi 10.1136/gutjnl-2011-300831.
- [2] King J, Kazanjian K, Matsumoto J, Reber HA, Yeh MW, Hines OJ, et al. Distal pancreatectomy: incidence of postoperative diabetes. J Gastrointest Surg 2008;12(9):1548-53 doi 10.1007/s11605-008-0560-5.
- [3] Falconi M, Mantovani W, Crippa S, Mascetta G, Salvia R, Pederzoli P. Pancreatic insufficiency after different resections for benign tumours. Br J Surg **2008**;95(1):85-91 doi 10.1002/bjs.5652.
- [4] Cataldegirmen G, Schneider CG, Bogoevski D, Koenig A, Kaifi JT, Bockhorn M, et al. Extended central pancreatic resection as an alternative for extended left or extended right resection for appropriate pancreatic neoplasms. Surgery 2010;147(3):331-8 doi 10.1016/j.surg.2009.10.027.
- [5] Zhu B, Sevick-Muraca EM. A review of performance of near-infrared fluorescence imaging devices used in clinical studies. Br J Radiol **2015**;88(1045):20140547- doi 10.1259/bjr.20140547.
- [6] Ghosh SC, Hernandez Vargas S, Rodriguez M, Kossatz S, Voss J, Carmon KS, et al. Synthesis of a Fluorescently Labeled (68)Ga-DOTA-TOC Analog for Somatostatin Receptor Targeting. ACS Med Chem Lett 2017;8(7):720-5 doi 10.1021/acsmedchemlett.7b00125.
- [7] Hernandez Vargas S, Kossatz S, Voss J, Ghosh SC, Tran Cao HS, Simien J, et al. Specific Targeting of Somatostatin Receptor Subtype-2 for Fluorescence-Guided Surgery. Clin Cancer Res 2019;25(14):4332-42 doi 10.1158/1078-0432.CCR-18-3312.